智飞生物最为人所知的身份,就是默沙东 HPV 疫苗 Gardasil 和 Gardasil 9 的中国代理商。自2017 年和2018 年, Gardasil 和 Gardasil 9 在中国获批以来,一直难以满足国内旺盛的需求。 HPV疫苗已成为智飞业务的基石。在2018年与默沙东达成Gardasil协议之前,智飞的营收徘徊在7亿元左右。2020年,总营收猛增至152亿元。 根...
MSD and Bio Farma Support the Implementation of the National HPV Immunization Program Read more Bio Farma and MSD Launched a Locally Manufactured 4-Valent HPV Vaccine in Indonesia MSD and Bio Farma sign a framework agreement for technology transfer partnership slide 3 of 3 We use the power...
“单打独斗”的Moderna,不敌背靠大树的BioNTech,两者2021年营收相差近50亿美元,排名第四。 智飞生物去年营收疫苗 47.5 亿美元,成为中国前两家跻身全球TOP 10的疫苗公司,“爆款”HPV疫苗(代理默沙东产品)功不可没。 疫情带来的超级市场之下,疫苗...
“单打独斗”的Moderna,不敌背靠大树的BioNTech,两者2021年营收相差近50亿美元,排名第四。 智飞生物去年营收疫苗 47.5 亿美元,成为中国前两家跻身全球TOP 10的疫苗公司,“爆款”HPV疫苗(代理默沙东产品)功不可没。 疫情带来的超级市场之下,疫苗行业天翻地覆,诸多此前籍籍无名者借势登顶,也让人看到了科兴生物、智飞...
Two MSD leaders share how we’re working to help protect communities from vaccine-preventable illnesses February 21, 2024 Empowering others to speak up about HPV-related cancers The impact of Gina’s diagnosis inspired her to help others prioritize their health ...
中国企业科兴生物2021年销售额超过 190 亿美元,压倒一众老牌疫苗巨头,逆袭榜单,全球排名第三。 “单打独斗”的Moderna,不敌背靠大树的BioNTech,两者2021年营收相差近50亿美元,排名第四。智飞生物去年营收疫苗 47.5 亿美元,成为中国前两家跻身全球TOP 10的疫苗公司,“爆款”HPV疫苗(代理默沙东产品)功不可没。
智飞生物去年营收疫苗 47.5 亿美元,成为中国前两家跻身全球TOP 10的疫苗公司,“爆款”HPV疫苗(代理默沙东产品)功不可没。 疫情带来的超级市场之下,疫苗行业天翻地覆,诸多此前籍籍无名者借势登顶,也让人看到了科兴生物、智飞生物逆袭的背后,中国及中低收入国家市场的巨大潜力。
The FDA approved GARDASIL [human papillomavirus quadrivalent (types 6, 11, 16, 18) vaccine, recombinant], for the prevention of cervical cancer caused by certain HPV types. In 2007, MSD committed to donating 3 million doses of GARDASIL over 5 years to support vaccination programs in the world...
and the company’s leadership are satisfied that the target for full-year non-COVID revenue growth of 6%-8% should be met this year. The huge windfall accrued from sales of Paxlovid and the BioNTech partnered COVID vaccine – estimated by GBI at over USD 90 billion over the last two ye...